Altman Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.13M | Sell |
9,809
-727
| -7% | -$161K | 0.88% | 48 |
|
|
2025
Q4 | $2.41M | Sell |
10,536
-5,338
| -34% | -$1.22M | 0.91% | 40 |
|
|
2025
Q3 | $3.68M | Buy |
15,874
+84
| +0.5% | +$17.1K | 1.41% | 15 |
|
|
2025
Q2 | $3M | Buy |
15,790
+341
| +2% | +$63.4K | 1.23% | 20 |
|
|
2025
Q1 | $3.01M | Buy |
15,449
+274
| +2% | +$53.3K | 1.39% | 16 |
|
|
2024
Q4 | $2.7M | Buy |
15,175
+283
| +2% | +$52K | 1.15% | 17 |
|
|
2024
Q3 | $2.94M | Buy |
14,892
+3,523
| +31% | +$658K | 1.31% | 16 |
|
|
2024
Q2 | $1.95M | Buy |
11,369
+78
| +0.7% | +$12.9K | 1.11% | 31 |
|
|
2024
Q1 | $2.04M | Sell |
11,291
-217
| -2% | -$37.4K | 0.99% | 29 |
|
|
2023
Q4 | $1.78M | Buy |
11,508
+153
| +1% | +$22.3K | 0.94% | 30 |
|
|
2023
Q3 | $1.69M | Buy |
+11,355
| New | +$1.67M | 1.06% | 19 |
|
|
2023
Q1 | $1.44M | Sell |
11,394
-9,226
| -45% | -$1.41M | 1.32% | 20 |
|
|
2022
Q4 | $3.24M | Sell |
20,620
-3,493
| -14% | -$536K | 2% | 7 |
|
|
2022
Q3 | $3.24M | Sell |
24,113
-635
| -3% | -$91.1K | 2.04% | 8 |
|
|
2022
Q2 | $3.47M | Sell |
24,748
-1,515
| -6% | -$231K | 1.98% | 11 |
|
|
2022
Q1 | $4.26M | Sell |
26,263
-438
| -2% | -$63.6K | 2.2% | 9 |
|
|
2021
Q4 | $3.52M | Buy |
26,701
+1,007
| +4% | +$119K | 2.15% | 8 |
|
|
2021
Q3 | $2.95M | Buy |
25,694
+57
| +0.2% | +$6.51K | 1.63% | 20 |
|
|
2021
Q2 | $2.92M | Buy |
25,637
+713
| +3% | +$80.3K | 1.65% | 19 |
|
|
2021
Q1 | $2.69M | Sell |
24,924
-932
| -4% | -$99.7K | 1.74% | 12 |
|
|
2020
Q4 | $2.77M | Sell |
25,856
-192
| -0.7% | -$18.5K | 1.74% | 14 |
|
|
2020
Q3 | $2.28M | Buy |
26,048
+396
| +2% | +$37.3K | 1.62% | 26 |
|
|
2020
Q2 | $2.52M | Sell |
25,652
-677
| -3% | -$59.6K | 2.14% | 11 |
|
|
2020
Q1 | $2.01M | Sell |
26,329
-1,446
| -5% | -$123K | 1.86% | 18 |
|
|
2019
Q4 | $2.46M | Sell |
27,775
-1,177
| -4% | -$97.7K | 1.96% | 22 |
|
|
2019
Q3 | $2.19M | Buy |
28,952
+492
| +2% | +$33.7K | 1.86% | 23 |
|
|
2019
Q2 | $2.07M | Buy |
28,460
+894
| +3% | +$70.3K | 1.74% | 27 |
|
|
2019
Q1 | $2.22M | Buy |
27,566
+714
| +3% | +$58.4K | 2.05% | 14 |
|
|
2018
Q4 | $2.48M | Sell |
26,852
-3,344
| -11% | -$294K | 2.71% | 7 |
|
|
2018
Q3 | $2.86M | Buy |
+30,196
| New | +$2.86M | 2.57% | 7 |
|
|
2018
Q2 | – | Sell |
-20,412
| Closed | -$1.93M | – | 70 |
|
|
2018
Q1 | $1.93M | Buy |
20,412
+16,114
| +375% | +$1.77M | 1.85% | 24 |
|
|
2017
Q4 | $416K | Buy |
+4,298
| New | +$405K | 0.36% | 61 |
|
Other funds holding ABBV
VCM
VPM
Altman Advisors's ABBV Position: Q1 2026 in Review
Altman Advisors reduced its AbbVie (ABBV) stake by 6.9% in Q1 2026, selling an estimated $161K and leaving 9,809 shares worth $2.13M. The position accounts for 0.88% of the portfolio, ranked #48.
Altman Advisors first reported a position in ABBV in Q4 2017 and has held it in 32 quarters since. The position peaked at $4.26M in Q1 2022. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Altman Advisors held 9,809 shares of AbbVie worth $2.13M as of Q1 2026.
- Altman Advisors sold 727 AbbVie shares in Q1 2026, an estimated $161K.
- AbbVie made up 0.88% of Altman Advisors's portfolio in Q1 2026, its #48 holding.
- Altman Advisors first reported a position in AbbVie in Q4 2017 and has held it in 32 quarters since.
- Altman Advisors's AbbVie position peaked at $4.26M in Q1 2022.
- 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Altman Advisors's 13F filing for Q1 2026, filed 5 May 2026.